It is the first time to bring the Prix Galien to China and honor China’s finest health innovations.

Founded in 1970, Prix Galien has become the Nobel Prize-equivalent for biopharmaceutical and medical technology research. It is an international network of 14 national-level awards that recognize outstanding achievements in improving the human condition through the development of innovative therapies.

The inaugural Prix Galien China aims to be the catalyst for China to become the world’s next innovation hub.

About Prix Galien

Awards Committee

Awards Categories

Innovative Product Award

The Prix Galien China – 2019 Innovative Product Award will be presented to the company that has developed the drug product launched on the China market and judged by the Jury to have made the most significant overall contribution to patient care in China in terms of efficacy, safety, benefits and innovation.

Research Award

The Prix Galien China- 2019 Research will be awarded to the researcher or the research team judged by the Jury to have made the most significant contribution to research leading or making a substantial contribution to the diagnosis, prevention or treatment of disease in China.

Digital Innovation for Impact Award

The judging panel are looking for an outstanding team or project that has developed the innovative digital solution that judged by the Jury to reduce barrier to access and inequality to the diagnosis, prevention or treatment of disease in China.

Apply for the Award

The application and nomination process for the inaugural Prix Galien China will open in September 2018. Entry submission is mandatory. Applicants are required to download the application form and send the submission to galien@rdpac.org The submission deadline is December 15th 2018.

Our Partners